LRRC32 Antikörper

Produktnummer ABIN2664991

Der Ratte Monoklonal anti-LRRC32 Antikörper wird verwendet zum Nachweis von LRRC32 in Proben von Maus. Er wurde validiert für IHC, CyTOF und ELISA (Capture).

Kurzübersicht für LRRC32 Antikörper (ABIN2664991)

Target: LRRC32 (Leucine Rich Repeat Containing 32 (LRRC32))

Reaktivität: Maus

Wirt: Ratte

Klonalität: Monoklonal

Konjugat: Dieser LRRC32 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (IHC), Mass Cytometry (CyTOF), ELISA (Capture)

Klon: F011-5

Produktdetails anti-LRRC32 Antikörper

Aufreinigung: The antibody was purified by affinity chromatography.

Isotyp: IgG2a kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu LRRC32

Target: LRRC32 (Leucine Rich Repeat Containing 32 (LRRC32))

Andere Bezeichnung: GARP

Hintergrund: Glycoprotein A Repetitions Predominant (GARP), also known as leucine rich repeat containing protein 32 (LRC32), is a 80 kD type I membrane glycoprotein with 20 leucine rich repeats in the extracellular portion of the protein. GARP was found on the surface of megakaryocytes, platelets, and activated Tregs. It serves as a receptor for latent TGF-β. Recent evidence suggests that GARP may play a role in controlling suppressor function of Tregs. A mutation in GARP has been reported in a large Samaritan kindred with Usher syndrome type 1. In addition, it has been found that GARP mRNA is highly amplified in different tumors, which indicates that tumor cells may use GARP to express TGF-β or to capture TGF-β from their surroundings, resulting in local suppression of anti-tumor immune responses or the induction of Tregs.

Pathways: Activated T Cell Proliferation